YC-1: A Potential Anticancer Drug Targeting Hypoxia-Inducible Factor 1

Abstract

The inhibition of HIF-1 alpha activity in tumors from YC-1-treated mice is associated with blocked angiogenesis and an inhibition of tumor growth. YC-1 has the potential to become the first antiangiogenic anticancer agent to target HIF-1 alpha.